Myelodysplastic syndrome macrophages have aberrant iron storage and heme oxygenase-1 expression

References

• Lawen A, Lane DJR. Mammalian iron homeostasis in health and disease: uptake, storage, transport, and molecular mechanisms of action. Antioxid Redox Signal. 2013;18: 2473–2507.
   PubMed Web of Science ®Google Scholar
• Koorts AM, Viljoen M. Ferritin and ferritin isoforms I: structure–function relationships, synthesis, degradation and secretion. Arch Physiol Biochem. 2007;113:30–54.
   PubMedGoogle Scholar
• Hughes DA, Stuart-Smith SE, Bain BJ. How should stainable iron in bone marrow films be assessed? J Clin Pathol. 2004;57:1038–1040.
   PubMed Web of Science ®Google Scholar
• Maines MD. The heme oxygenase system: update 2005. Antioxid Redox Signal. 2005;7:1761–1766.
   PubMed Web of Science ®Google Scholar
• Biswas C, Shah N, Muthu M, et al. Nuclear heme oxygenase-1 (HO-1) modulates subcellular distribution and activation of Nrf2 impacting metabolic and anti-oxidant defenses. J Biol Chem. 2014.
   Web of Science ®Google Scholar
• Mc Cauley LK, Dalli J, Koh AJ, et al. Cutting edge: parathyroid hormone facilitates macrophage efferocytosis in bone marrow via proresolving mediators Resolvin D1 and Resolvin D2. J Immunol Baltim Md. 2014:193:26–29.
   Google Scholar
• Chow A, Lucas D, Hidalgo A, et al. Bone marrow CD169 + macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med. 2011;208:261–271.
   PubMed Web of Science ®Google Scholar
• Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409:198–201.
   PubMed Web of Science ®Google Scholar
• Schaer DJ, Schaer CA, Buehler PW, et al. CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. Blood. 2006;107:373–380.
   PubMed Web of Science ®Google Scholar
• Schaer CA, Schoedon G, Imhof A, et al. Constitutive endocytosis of CD163 mediates hemoglobin–heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. Circ Res. 2006;99:943–950.
   PubMed Web of Science ®Google Scholar
• Lau SK, Chu PG, Weiss LM. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol. 2004;122:794–801.
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Schwartz EJ, West RB, et al. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol. 2005;29:617–624.
   PubMed Web of Science ®Google Scholar
• Qian B-Z, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39–51.
   PubMed Web of Science ®Google Scholar
• Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 2014;105:1–8.
   PubMed Web of Science ®Google Scholar
• Barros MHM, Hauck F, Dreyer JH, et al. Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One. 2013;8: e80908.
   PubMed Web of Science ®Google Scholar
• Arnold JN, Magiera L, Kraman M, et al. Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1. Cancer Immunol Res. 2014;2:121–126.
   PubMed Web of Science ®Google Scholar
• Garcia-Santos D, Schranzhofer M, Horvathova M, et al. Heme oxygenase 1 is expressed in murine erythroid cells where it controls the level of regulatory heme. Blood. 2014;123:2269–2277.
   PubMed Web of Science ®Google Scholar
• Wegiel B, Hedblom A, Li M, et al. Heme oxygenase-1 derived carbon monoxide permits maturation of myeloid cells. Cell Death Dis. 2014;5:e1139.
   PubMed Web of Science ®Google Scholar
• Vanella L, Kim DH, Asprinio D, et al. HO-1 expression increases mesenchymal stem cell-derived osteoblasts but decreases adipocyte lineage. Bone. 2010;46:236–243.
   PubMed Web of Science ®Google Scholar
• Kode A, Manavalan JS, Mosialou I, et al. Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature. 2014;506:240–244.
   PubMed Web of Science ®Google Scholar
• Johnson RC, Kurzer JH, Greenberg PL, et al. Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival. Am J Clin Pathol. 2014;142:795–802.
   PubMed Web of Science ®Google Scholar
• Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Lee Harris N, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2008. p. 87–107.
   Google Scholar
• Greenberg PL, Attar E, Bennett JM, et al. NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. J Natl Compr Cancer Netw JNCCN. 2013;11: 838–874.
   PubMed Web of Science ®Google Scholar
• Flores-Figueroa E, Varma S, Montgomery K, et al. Distinctive contact between CD34 + hematopoietic progenitors and CXCL12 + CD271 + mesenchymal stromal cells in benign and myelodysplastic bone marrow. Lab Invest. 2012;92:1330–1341.
   PubMed Web of Science ®Google Scholar
• Kamentsky L, Jones TR, Fraser A, et al. Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. Bioinforma Oxf Engl. 2011;27:1179–1180.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
   PubMed Web of Science ®Google Scholar
• Hartmann J, Braulke F, Sinzig U, et al. Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes. Leuk Res. 2013;37:327–332.
   PubMed Web of Science ®Google Scholar
• Shenoy N, Vallumsetla N, Rachmilewitz E, et al. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124: 873–881.
   PubMed Web of Science ®Google Scholar
• Navone R, Azzoni L, Valente G. Immunohistochemical assessment of ferritin in bone marrow trephine biopsies: correlation with marrow hemosiderin. Acta Haematol. 1988;80:194–198.
   PubMed Web of Science ®Google Scholar
• Santini V, Girelli D, Sanna A, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PloS One. 2011;6:e23109.
   PubMed Web of Science ®Google Scholar
• Cui R, Gale RP, Zhu G, et al. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions. Leuk Res. 2014;38:545–550.
   PubMed Web of Science ®Google Scholar
• Wysoczynski M, Ratajczak J, Pedziwiatr D, et al. Identification of heme oxygenase 1 (HO-1) as a novel negative regulator of mobilization of hematopoietic stem/progenitor cells. Stem Cell Rev. 2014;11:110–118.
   Web of Science ®Google Scholar
• Thomsen JH, Etzerodt A, Svendsen P, et al. The haptoglobin-CD163-heme oxygenase-1 pathway for hemoglobin scavenging. Oxid Med Cell Longev. 2013;2013: 523652.
   PubMed Web of Science ®Google Scholar
• Delaby C, Rondeau C, Pouzet C, et al. Subcellular localization of iron and heme metabolism related proteins at early stages of erythrophagocytosis. PloS One. 2012; 7:e42199.
   PubMed Web of Science ®Google Scholar
• Haldar M, Kohyama M, So AY-L, et al. Heme-mediated SPI-C induction promotes monocyte differentiation into iron-recycling macrophages. Cell. 2014;156:1223–1234.
   PubMed Web of Science ®Google Scholar